TABLE 3.
Antiserum directed against (NTHI strain): | Adjuvant | Mean relative affinity (RU ± SD)a
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
LB1ps1 | LB1ps2 | LB1ps3 | LB1(2a) | LB1(2b) | LB1(3) | Region 1 | Region 2 | LB1(1) region 3 | Region 4 | LB1 (40-mer) | ||
Whole OMP (1128) | CFA | 32 ± 3 | 72 ± 7 | 23 ± 8 | 38 ± 2 | 40 ± 5 | 35 ± 3 | 21 ± 9 | 25 ± 9 | 32 ± 10 | 33 ± 10 | 47 ± 4 |
Isolated P5-fimbrin (1128) | CFA | 24 ± 9 | 32 ± 5 | 9 ± 3 | 38 ± 3 | 33 ± 10 | 56 ± 6 | 20 ± 4 | 22 ± 11 | 50 ± 5 | 41 ± 6 | 110 ± 15 |
LB1 | CFA | 40 ± 7 | 49 ± 1 | 885 ± 67 | 38 ± 6 | 211 ± 27 | 564 ± 54 | 38 ± 12 | 21 ± 10 | 1,453 ± 70 | 45 ± 14 | 1,530 ± 63 |
LPD-LB1(f)2,1,3 | A1PO4 MPL | 30 ± 7 | 25 ± 9 | 17 ± 1 | 29 ± 4 | 40 ± 6 | 63 ± 3 | 35 ± 11 | 19 ± 9 | 33 ± 10 | 43 ± 10 | 10 ± 5 |
Values of ≥100 RU are in boldface.